Insurers’ attacks on medicines often fail to account for the value of a medicine brings to society, the health care system and individual patients. This is exactly what the nation’s health insurers did in a recent blog post about a class of innovative biologic drugs that has revolutionized care for patients with several autoimmune diseases, including those in rheumatology, dermatology and gastroenterology.
The following is just one voice on the value of these medicines, and what it means for patients to have access to the right medicine, at the right time.
For years my job has been to work with physicians, patients and other health advocates in state capitals across the South to promote public policies that will help folks who are struggling to get better coverage for the medicines they need to live healthier, more productive lives. I’ve been armed with facts and figures and good policy arguments and I know how to talk to lawmakers about why it is critical for patients to get the right treatments at the right time.
Then, four years ago, I learned more than I ever thought I would.
I, a relatively young person with no real history of health problems, was now a patient.